Product news

Share this article:

GlaxoSmithKline announced that the European Commission has granted a marketing authorization for its cervical cancer vaccine, Cervarix, for all 27 European member states.  Cervarix is indicated for the prevention of precancerous cervical lesions and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18. The indication is based on data generated in girls and women aged between 10 and 25.


Novo Nordisk announced that its Norditropin (somatropin [rDNA origin] injection) received approval from the FDA for the treatment of children with short stature associated with Turner syndrome.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.